140 related articles for article (PubMed ID: 25703515)
1. Potency labeling of novel factor VIII and factor IX concentrates: past experience and current strategy.
Hubbard AR
Semin Thromb Hemost; 2015 Nov; 41(8):849-54. PubMed ID: 25703515
[TBL] [Abstract][Full Text] [Related]
2. Potency determination of factor VIII and factor IX for new product labelling and postinfusion testing: challenges for caregivers and regulators.
Dodt J; Hubbard AR; Wicks SJ; Gray E; Neugebauer B; Charton E; Silvester G
Haemophilia; 2015 Jul; 21(4):543-9. PubMed ID: 25623631
[TBL] [Abstract][Full Text] [Related]
3. Recombinant factor IX: discrepancies between one-stage clotting and chromogenic assays.
Wilmot HV; Hogwood J; Gray E
Haemophilia; 2014 Nov; 20(6):891-7. PubMed ID: 24800651
[TBL] [Abstract][Full Text] [Related]
4. The traceability of commercial plasma calibrators to the plasma International Standards for factor VIII and factor IX.
Wilmot HV; Rakowski K; Gray E
Int J Lab Hematol; 2020 Dec; 42(6):810-818. PubMed ID: 32638532
[TBL] [Abstract][Full Text] [Related]
5. Recombinant to modified factor VIII and factor IX - chromogenic and one-stage assays issues.
Kitchen S; Kershaw G; Tiefenbacher S
Haemophilia; 2016 Jul; 22 Suppl 5():72-7. PubMed ID: 27405680
[TBL] [Abstract][Full Text] [Related]
6. Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations.
Barrowcliffe TW; Raut S; Sands D; Hubbard AR
Semin Thromb Hemost; 2002 Jun; 28(3):247-56. PubMed ID: 12098084
[TBL] [Abstract][Full Text] [Related]
7. Summary of the WHO hearing on the development of product-specific reference materials for coagulation factor VIII and factor IX products.
Ovanesov MV; Williams SC; Nübling CM; Dodt J; Hilger A; Maryuningsih Y; Gray E
Biologicals; 2020 Sep; 67():88-93. PubMed ID: 32847723
[TBL] [Abstract][Full Text] [Related]
8. Monitoring of modified factor VIII and IX products.
Kitchen S; Gray E; Mertens K
Haemophilia; 2014 May; 20 Suppl 4():36-42. PubMed ID: 24762273
[TBL] [Abstract][Full Text] [Related]
9. A Review of Factor VIII and Factor IX Assay Methods for Monitoring Extended Half-Life Products in Hemophilia A and B.
Abraham S; Duncan EM
Methods Mol Biol; 2023; 2663():569-588. PubMed ID: 37204737
[TBL] [Abstract][Full Text] [Related]
10. Considerations on activity assay discrepancies in factor VIII and factor IX products.
Ovanesov MV; Jackson JW; Golding B; Lee TK
J Thromb Haemost; 2021 Sep; 19(9):2102-2111. PubMed ID: 34145730
[TBL] [Abstract][Full Text] [Related]
11. Assaying the circulating factor VIII activity in hemophilia A patients treated with recombinant factor VIII products.
Mikaelsson M; Oswaldsson U
Semin Thromb Hemost; 2002 Jun; 28(3):257-64. PubMed ID: 12098085
[TBL] [Abstract][Full Text] [Related]
12. Clinical application of a chromogenic substrate method for determination of factor VIII activity.
Rosén S; Andersson M; Blombäck M; Hägglund U; Larrieu MJ; Wolf M; Boyer C; Rothschild C; Nilsson IM; Sjörin E
Thromb Haemost; 1985 Dec; 54(4):818-23. PubMed ID: 3937277
[TBL] [Abstract][Full Text] [Related]
13. Factor VIII assay mimicking in vivo coagulation conditions.
Kusch M; Grundmann C; Keitel S; König H
Haemophilia; 2014 Mar; 20(2):e164-70. PubMed ID: 24286249
[TBL] [Abstract][Full Text] [Related]
14. Potency estimates for recombinant factor IX in the one-stage clotting assay are influenced by more than just the choice of activated partial thromboplastin time reagent.
Wilmot HV; Gray E
Haemophilia; 2018 Sep; 24(5):e363-e368. PubMed ID: 30051554
[TBL] [Abstract][Full Text] [Related]
15. Advantages, disadvantages and optimization of one-stage and chromogenic factor activity assays in haemophilia A and B.
Adcock DM; Strandberg K; Shima M; Marlar RA
Int J Lab Hematol; 2018 Dec; 40(6):621-629. PubMed ID: 29979821
[TBL] [Abstract][Full Text] [Related]
16. One-stage vs. chromogenic assays in haemophilia A.
Potgieter JJ; Damgaard M; Hillarp A
Eur J Haematol; 2015 Feb; 94 Suppl 77():38-44. PubMed ID: 25560793
[TBL] [Abstract][Full Text] [Related]
17. Potency estimation of recombinant factor VIII: effect of assay method and standard.
Hubbard AR; Bevan SA; Weller LJ
Br J Haematol; 2001 May; 113(2):533-6. PubMed ID: 11380427
[TBL] [Abstract][Full Text] [Related]
18. Issues with the assay of factor VIII activity in plasma and factor VIII concentrates.
Lundblad RL; Kingdon HS; Mann KG; White GC
Thromb Haemost; 2000 Dec; 84(6):942-8. PubMed ID: 11154139
[TBL] [Abstract][Full Text] [Related]
19. Validation of a procedure for potency assessing of a high purity factor VIII concentrate--comparison of different factor VIII coagulant assays and effect of prediluent.
Mazurier C; Parquet-Gernez A; Goudemand M
Thromb Haemost; 1990 Oct; 64(2):251-5. PubMed ID: 2125374
[TBL] [Abstract][Full Text] [Related]
20. Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity.
Perot E; Enjolras N; Le Quellec S; Indalecio A; Girard J; Negrier C; Dargaud Y
Thromb Res; 2015 May; 135(5):1017-24. PubMed ID: 25795563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
